OncoSil Medical Ltd (ASX:OSL) has outlined today in its 2016 Annual General Meeting (AGM) Notice of Meeting, that Martin Rogers has confirmed to the board that he is not standing for re-election at this year's AGM.
Accordingly, Rogers resignation as a director will be effective on conclusion of the meeting, set for 11am (AEDT) on Tuesday 18 October 2016 in Sydney.
Dr. Roger Aston, chairman, noted in his letter to shareholders that the company continues to progress towards its goals for the OncoSil™ radiation treatment of pancreatic cancer.
OncoSil recently delivered a significant milestone on the pathway to commercialisation, as it received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA).
The IDE Approval is beneficial in supporting OncoSil's ongoing CE mark application, with the company remaining confident of obtaining the CE Mark in the near term.
Key appointments
In today's Annual Report for 2016, OncoSil highlighted that several key appointments were completed to support the continued growth and development of the company.
These appointments include David James, Michael Warrener, and Charles Rowland as the President of U.S. Operations.
Rowland is a highly credentialed healthcare executive including four years’ service as President of Sirtex Medical U.S.
Broker spotlight
OncoSil has been receiving some strong broker attention recently, as the company moves closer to commercial revenue.
OncoSil last traded at $0.125.
- Wilsons Research $0.48 per share.
- Bell Potter $0.33 per share.
- WilsonHTM $0.48 per share.
- Van Leeuwenhoek (earlier in year) $0.80 per share.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.